Gums Tyler H, Carter Barry L, Milavetz Gary, Buys Lucinda, Rosenkrans Kurt, Uribe Liz, Coffey Christopher, MacLaughlin Eric J, Young Rodney B, Ables Adrienne Z, Patel-Shori Nima, Wisniewski Angela
Department of Pharmacy Practice & Science, University of Iowa College of Pharmacy, Iowa City, Iowa; Department of Family Medicine, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa.
Pharmacotherapy. 2014 Oct;34(10):1033-42. doi: 10.1002/phar.1468. Epub 2014 Aug 20.
To determine if asthma control improves in patients who receive physician-pharmacist collaborative management (PPCM) during visits to primary care medical offices.
Prospective pre-post study of patients who received the intervention in primary care offices for 9 months. The primary outcome was the sum of asthma-related emergency department (ED) visits and hospitalizations at 9 months before, 9 months during, and 9 months after the intervention. Events were analyzed using linear mixed-effects regression. Secondary analysis was conducted for patients with uncontrolled asthma (Asthma Control Test [ACT] less than 20). Additional secondary outcomes included the ACT, the Asthma Quality of Life Questionnaire by Marks (AQLQ-M) scores, and medication changes.
Pharmacists provided patients with an asthma self-management plan and education and made pharmacotherapy recommendations to physicians when appropriate.
Of 126 patients, the number of emergency department (ED) visits and/or hospitalizations decreased 30% during the intervention (p=0.052) and then returned to preenrollment levels after the intervention was discontinued (p=0.83). Secondary analysis of patients with uncontrolled asthma at baseline (ACT less than 20), showed 37 ED visits and hospitalizations before the intervention, 21 during the intervention, and 33 after the intervention was discontinued (p=0.019). ACT and AQLQ-M scores improved during the intervention (ACT mean absolute increase of 2.11, AQLQ-M mean absolute decrease of 4.86, p<0.0001) and sustained a stable effect after discontinuation of the intervention. Inhaled corticosteroid use increased during the intervention (p=0.024).
The PPCM care model reduced asthma-related ED visits and hospitalizations and improved asthma control and quality of life. However, the primary outcome was not statistically significant for all patients. There was a significant reduction in ED visits and hospitalizations during the intervention for patients with uncontrolled asthma at baseline. Our findings support the need for further studies to investigate asthma outcomes achievable with the PPCM model.
确定在初级保健医疗机构就诊期间接受医生 - 药剂师协作管理(PPCM)的患者哮喘控制情况是否得到改善。
对在初级保健机构接受为期9个月干预的患者进行前瞻性前后对照研究。主要结局是干预前9个月、干预期间9个月和干预后9个月与哮喘相关的急诊科(ED)就诊和住院次数之和。使用线性混合效应回归分析这些事件。对哮喘控制不佳(哮喘控制测试[ACT]低于20)的患者进行二次分析。其他次要结局包括ACT、Marks哮喘生活质量问卷(AQLQ - M)得分以及药物治疗的变化。
药剂师为患者提供哮喘自我管理计划和教育,并在适当时向医生提出药物治疗建议。
126例患者中,干预期间急诊科(ED)就诊和/或住院次数减少了30%(p = 0.052),干预停止后又回到了入组前水平(p = 0.83)。对基线时哮喘控制不佳(ACT低于20)的患者进行二次分析显示,干预前有37次ED就诊和住院,干预期间为21次,干预停止后为33次(p = 0.019)。干预期间ACT和AQLQ - M得分有所改善(ACT平均绝对增加2.11,AQLQ - M平均绝对减少4.86,p < 0.0001),干预停止后仍保持稳定效果。干预期间吸入性糖皮质激素的使用增加(p = 0.024)。
PPCM护理模式减少了与哮喘相关的ED就诊和住院次数,改善了哮喘控制和生活质量。然而,主要结局对所有患者而言在统计学上并不显著。对于基线时哮喘控制不佳的患者,干预期间ED就诊和住院次数有显著减少。我们的研究结果支持需要进一步研究以探讨PPCM模式可实现的哮喘结局。